Assessment and treatment of severe pancreatitis. Protease inhibitor

Digestion

Volumn 60, Issue SUPPL. 1, 1999, Pages 5-8

  Bassi, Claudio ^a   Falconi, Massimo ^a   Caldiron, Erminia ^a   Salvia, Roberto ^a   Sartori, Nora ^a   Butturini, Giovanni ^a   Contro, Conrado ^a   Marcucci, Stefano ^a   Casetti, Luca ^a   Pederzoli, Paolo ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Multiple drugs approach; Pancreatitis, assessment and treatment; Post ERCP acute pancreatitis; Protease inhibitor, clinical applications

Indexed keywords

ANTIBIOTIC AGENT; APROTININ; GABEXATE MESILATE; PLACEBO; PROTEINASE INHIBITOR;

ACUTE PANCREATITIS; CLINICAL TRIAL; COMPLICATION; CONFERENCE PAPER; DOUBLE BLIND PROCEDURE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL;

EID: 0032984126     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051445     Document Type: Conference Paper

References (18)

1. Steinberg WM, Schlessmann SE: Treatment of acute pancreatitis: Comparison of animal and human studies. Gastroenterology 1987;93: 1420-1427.
2. Trapnell JE, Rigby CC, Talbot CH, Duncan EHL: A controlled trial of trasylol in the treatment of acute pancreatitis. Br J Surg 1974;61: 177-182.
3. Cox AG: Death from acute pancreatitis: MCR multicentre trial of glucagon and atropinin. Lancet 1977;24:632-635.
4. Imrie CW, Benjamin IS, Ferguson JC, MaKay AJ, Mackenzie IM, O'Neill J, Blumgart LH: A single-centre double-blind trial of trasylol therapy in primary acute pancreatitis. Br J Surg 1978;65:337-341.
5. Tanaka N, Tsuchiya R, Ishii K: Comparative clinical study of FOY and trasylol in acute pancreatitis. Adv Exp Med Biol 1979;1208:367-377.
6. Yang CY, Chang-Chien CS, Liaw YF: Controlled trial of protease inhibitor gabexate mesilate (Foy) in the treatment of acute pancreatitis. Pancreas 1987;2:698-700.
7. Goebell H, for the German Pancreatitis Study Group: Multicenter double-blind study of gabexate mesilate (Foy), given intravenously in low dose in acute pancreatitis. Digestion 1988; 40:83.
8. Scuro LA, Cavallini G, Bovo P, Riela A, Bassi C, et al: Gabexate mesilate (Foy) treatment of acute pancreatitis. Clin Trial J 1990;27:39-49.
9. Harada H, Miiyake H, Ochi K, Tanaka J, Kimura I: Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol 1991;9:75-79.
10. Valderrama R, Perz Mateo M, Navarro S, Vasquez N, Sajose L, Adrian MV, Estruch J: Multi-center double-blind trial of gabexate mesilate (Foy) in acute pancreatitis. Digestion 1992;51: 65-70.
11. Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockman F, et al: Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993;104:1165-1170.
12. Pederzoli P, Cavallini G, Falconi M, Bassi C, for the Italian GA.ME.PA. Study Group: Gabexate mesilate versus aprotinin in human acute pancreatitis: A prospective, randomised, double-blind multicenter study. Int J Pancreatol 1993;14:117-124.
13. Messori A, Rampazzo R, Scroccaro G, Olivato R, Bassi C, Falconi M, Pederzoli P, Martini N: Effectiveness of gabexate mesilate in acute pancreatitis: A meta-analysis. Dig Dis Sci 1995;40: 734-738.
14. Warshaw A: Damage prevention versus damage control in acute pancreatitis. Gastroenterology 1993;104:1216-1218.
15. Yoschida T: Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993;105: 1922-1923.
16. Cavallini G, Tittobello A, Frulloni L, et al: Gabexate for the prevention of pancreatic damage related to endoscopie retrograde cholangiopancreatography. N Engl J Med 1996; 335:919-923.
17. Takeda K, Matsumo S, Sunamura M, Kakugama Y: Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg 1996;171: 394-398.
18. Uomo G, Visconti M, Manes GP, Calise F, Laccetti M, Rabiatti PG: Nonsurgical treatment of acute necrotizing pancreatitis. Pancreas 1996;12:142-148.